GEMM are relevant models for assessing immunotherapy efficacy, as genetic alterations, such as those occurring in the Tp53 gene, may be involved in modulating the tumor immune microenvironment, such as in the increased expression of PD-L1 [133] or the production of pro-inflammatory cytokines [134]. Here, CD274 is linked to neoplasm.